Gilead Sciences (GILD)
Develops HIV antivirals, liver-disease medicines, and oncology therapies including CAR-T treatments.
$152.72
After hours+0.05 (+0.03%)
At close$152.67(+1.40%)
Something off on this page? Send us feedback.
Next report
Oct 29, 26
in 37 days
EPS estimate
$2.12
Revenue estimate
$7.77B
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25Apr '25Aug '25Oct '25Feb '26May '26Aug '26Oct '26
Reported$1.90$1.81$2.01$2.47$1.86$2.03−$6.75Pending
Estimate$1.74$1.78$1.96$2.13$1.81$1.91−$7.25$2.12
Surprise+9.2%+1.7%+2.6%+16.0%+2.8%+6.3%+6.9%—
RevenueReportedEstimate
Feb '25Apr '25Aug '25Oct '25Feb '26May '26Aug '26Oct '26
Reported$7.57B$6.67B$7.08B$7.77B$7.93B$6.96B$7.80BPending
Estimate$7.15B$6.81B$6.98B$7.45B$7.69B$6.91B$7.40B$7.77B
Surprise+5.8%−2.1%+1.4%+4.3%+3.1%+0.7%+5.5%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | $0.00 | — | — |
| Sep 2028 | $0.00 | — | — |
| Jun 2028 | $0.00 | — | — |
| Mar 2028 | $0.00 | — | — |
| Dec 2027 | $2.84 | — | — |
| Sep 2027 | $2.53 | — | — |
| Jun 2027 | $2.49 | — | — |
| Mar 2027 | $2.30 | — | — |
| Dec 2026 | $2.14 | — | — |
| Oct 2026 | $2.12 | — | — |
| Aug 2026 | −$7.25 | −$6.75 | +6.9% |
| May 2026 | $1.91 | $2.03 | +6.3% |
| Feb 2026 | $1.81 | $1.86 | +2.8% |
| Oct 2025 | $2.13 | $2.47 | +16.0% |
| Aug 2025 | |||
| Apr 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| Apr 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| Apr 2023 | |||
| Feb 2023 | |||
| Oct 2022 | |||
| Aug 2022 | |||
| Apr 2022 | |||
| Feb 2022 | |||
| Oct 2021 | |||
| Jul 2021 | |||
| Apr 2021 | |||
| Feb 2021 | |||
| Oct 2020 | |||
| Jul 2020 | |||
| Apr 2020 | |||
| Feb 2020 | |||
| Oct 2019 | |||
| Jul 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Oct 2018 | |||
| Jul 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Oct 2017 | |||
| Jul 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Jul 2016 | |||
| Apr 2016 | |||
| Feb 2016 | |||
| Oct 2015 | |||
| Jul 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | $0.00 | — | — | $8.86B | — | — | — |
| Sep 2028 | $0.00 | — | — | $8.70B | — | — | — |
| Jun 2028 | $0.00 | — | — | $8.43B | — | — | — |
| Mar 2028 | $0.00 | — | — | $7.87B | — | — | — |
| Dec 2027 | $2.84 | — | — | $9.00B | — | — | — |
| Sep 2027 | $2.53 | — | — | $8.24B | — | — | — |
| Jun 2027 | $2.49 | — | — | $8.02B | — | — | — |
| Mar 2027 | $2.30 | — | — | $7.44B | — | — | — |
| Dec 2026 | $2.14 | — | — | $8.13B | — | — | — |
| Oct 29, 2026 | $2.12 | — | — | $7.77B | — | — | — |
| Aug 4, 2026 | −$7.25 | −$6.75 | +6.9% | $7.40B | $7.80B | +5.5% | −2.6% |
| May 7, 2026 | $1.91 | $2.03 | +6.3% | $6.91B | $6.96B | +0.7% | −2.0% |
| Feb 10, 2026 | $1.81 | $1.86 | +2.8% | $7.69B | $7.93B | +3.1% | +5.8% |
| Oct 30, 2025 | $2.13 | $2.47 | +16.0% | $7.45B | $7.77B | +4.3% | +1.1% |
| Aug 7, 2025 | |||||||
| Apr 24, 2025 | |||||||
| Feb 11, 2025 | |||||||
| Nov 6, 2024 | |||||||
| Aug 8, 2024 | |||||||
| Apr 25, 2024 | |||||||
| Feb 6, 2024 | |||||||
| Nov 7, 2023 | |||||||
| Aug 3, 2023 | |||||||
| Apr 27, 2023 | |||||||
| Feb 2, 2023 | |||||||
| Oct 27, 2022 | |||||||
| Aug 2, 2022 | |||||||
| Apr 28, 2022 | |||||||
| Feb 1, 2022 | |||||||
| Oct 28, 2021 | |||||||
| Jul 29, 2021 | |||||||
| Apr 29, 2021 | |||||||
| Feb 4, 2021 | |||||||
| Oct 28, 2020 | |||||||
| Jul 30, 2020 | |||||||
| Apr 30, 2020 | |||||||
| Feb 4, 2020 | |||||||
| Oct 24, 2019 | |||||||
| Jul 30, 2019 | |||||||
| May 2, 2019 | |||||||
| Feb 4, 2019 | |||||||
| Oct 25, 2018 | |||||||
| Jul 25, 2018 | |||||||
| May 1, 2018 | |||||||
| Feb 6, 2018 | |||||||
| Oct 26, 2017 | |||||||
| Jul 26, 2017 | |||||||
| May 2, 2017 | |||||||
| Feb 7, 2017 | |||||||
| Nov 1, 2016 | |||||||
| Jul 25, 2016 | |||||||
| Apr 28, 2016 | |||||||
| Feb 2, 2016 | |||||||
| Oct 27, 2015 | |||||||
| Jul 28, 2015 |